Arcutis Drug Patent Portfolio
Arcutis owns 1 orange book drug protected by 13 US patents Given below is the list of Arcutis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707454 | Topical roflumilast formulation having antifungal properties | 03 Dec, 2041 | Active |
| US11129818 | Topical roflumilast formulation having improved delivery and plasma half life | 25 Aug, 2037 | Active |
| US10940142 | Inhibition of crystal growth of roflumilast | 07 Jun, 2037 | Active |
| US11793796 | Inhibition of crystal growth of roflumilast | 07 Jun, 2037 | Active |
| US11819496 | Topical roflumilast formulation having improved delivery and plasma half-life | 07 Jun, 2037 | Active |
| US11992480 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | 07 Jun, 2037 | Active |
| US12005051 | Topical roflumilast formulation having improved delivery and plasma half life | 07 Jun, 2037 | Active |
| US12005052 | Topical roflumilast formulation having improved delivery and plasma half-life | 07 Jun, 2037 | Active |
| US12011437 | Roflumilast formulations with an improved pharmacokinetic profile | 07 Jun, 2037 | Active |
| US12016848 | Roflumilast formulations with an improved pharmacokinetic profile | 07 Jun, 2037 | Active |
| US12042487 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | 07 Jun, 2037 | Active |
| US9884050 | Inhibition of crystal growth of roflumilast | 07 Jun, 2037 | Active |
| US9907788 | Inhibition of crystal growth of roflumilast | 07 Jun, 2037 | Active |
Latest Legal Activities on Arcutis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Arcutis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US9884050 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 May, 2024 | US10940142 |
|
Email Notification
Critical
| 11 Mar, 2024 | US9884050 |
| Mail O.P. Petition Decision | 11 Mar, 2024 | US9884050 |
|
Mail-Petition Decision - Dismissed
Critical
| 07 Mar, 2024 | US9884050 |
|
Petition Decision - Dismissed
Critical
| 06 Mar, 2024 | US9884050 |
| O.P. Petition Decision | 05 Mar, 2024 | US9884050 |
|
Email Notification
Critical
| 12 Feb, 2024 | US11819496 |
| Mail O.P. Petition Decision | 12 Feb, 2024 | US11819496 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 08 Feb, 2024 | US11819496 |
| Record Petition Decision of Granted to Make Entity Status large | 07 Feb, 2024 | US11819496 |
|
Email Notification
Critical
| 01 Feb, 2024 | US11707454 |
| Mail O.P. Petition Decision | 01 Feb, 2024 | US11707454 |
| O.P. Petition Decision | 30 Jan, 2024 | US11819496 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 30 Jan, 2024 | US11707454 |
Arcutis's Family Patents
Arcutis drugs have patent protection in a total of 11 countries. It's US patent count contributes only to 39.4% of its total global patent coverage. Click
below to unlock the full patent family tree.
Arcutis Drug List
Given below is the complete list of Arcutis's drugs and the patents protecting them.
1. Zoryve
Zoryve is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707454 | Topical roflumilast formulation having antifungal properties |
03 Dec, 2041
(17 years from now)
| Active |
| US11129818 | Topical roflumilast formulation having improved delivery and plasma half life |
25 Aug, 2037
(12 years from now)
| Active |
| US10940142 | Inhibition of crystal growth of roflumilast |
07 Jun, 2037
(12 years from now)
| Active |
| US11793796 | Inhibition of crystal growth of roflumilast |
07 Jun, 2037
(12 years from now)
| Active |
| US11819496 | Topical roflumilast formulation having improved delivery and plasma half-life |
07 Jun, 2037
(12 years from now)
| Active |
| US11992480 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
07 Jun, 2037
(12 years from now)
| Active |
| US12005051 | Topical roflumilast formulation having improved delivery and plasma half life |
07 Jun, 2037
(12 years from now)
| Active |
| US12005052 | Topical roflumilast formulation having improved delivery and plasma half-life |
07 Jun, 2037
(12 years from now)
| Active |
| US12011437 | Roflumilast formulations with an improved pharmacokinetic profile |
07 Jun, 2037
(12 years from now)
| Active |
| US12016848 | Roflumilast formulations with an improved pharmacokinetic profile |
07 Jun, 2037
(12 years from now)
| Active |
| US12042487 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
07 Jun, 2037
(12 years from now)
| Active |
| US9884050 | Inhibition of crystal growth of roflumilast |
07 Jun, 2037
(12 years from now)
| Active |
| US9907788 | Inhibition of crystal growth of roflumilast |
07 Jun, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zoryve's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List